Public Opinion and America's Experimentation with Cannabis Reform
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Medical Cannabis Q&A
Medical Cannabis Q&A 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing a variety of active cannabinoids and terpenes, which patients take for medical reasons, after interacting with and obtaining authorization from their health care practitioner. 2. What are the main active ingredients? The chemical ingredients of cannabis are called cannabinoids. The two main therapeutic ones are: THC:CBD a. Tetrahydrocannabinol (THC) is a partial agonist of CB1 and CB2 receptors. It is psychoactive and produces the euphoric effect. Each cannabis product will contain THC and CBD, however b. Cannabidiol (CBD) has a weak affinity for CB1 and CB2 receptors and appears the THC: CBD ratio will differ to exert its activity by enhancing the positive effects of the body’s endogenous depending on the product. cannabinoids. 3. Why do patients take it? Medical cannabis may be used to alleviate symptoms for a variety of conditions. It has most commonly been used in neuropathic pain and other chronic pain conditions. There is limited, but developing clinical evidence surrounding its safety and efficacy, and it does not currently have an approved Health Canada indication. 4. How do patients take it? Cannabis can be smoked, vaporized, taken orally, sublingually, topically or rectally. Different routes of administration will result in different pharmacokinetic and pharmacodynamic properties of the drug. 5. Is it possible to develop dependence on medical cannabis? Yes, abrupt discontinuation after long-term use may result in withdrawal symptoms. Additionally, chronic use may result in psychological dependence. -
The Green Regulatory Arbitrage
Table of Contents I. EXECUTIVE SUMMARY ...................................................................................................... 1 II. PROHIBITION - HOW CANNABIS BECAME ILLEGAL ..................................................... 4 III. THE LEGAL LANDSCAPE .................................................................................................... 7 A. Federal Law And Its Impact On The Cannabis Industry ..................................................... 7 1. Cannabis Is A Schedule 1 Substance ............................................................................ 7 2. Access To Capital Markets Restricted ......................................................................... 9 3. Banking Services Limited .......................................................................................... 10 4. Tax Burdens .............................................................................................................. 11 5. Interstate And International Commerce Restrictions ................................................. 11 6. Insurance Options Limited ........................................................................................ 12 7. Medical Research And Clinical Trials Stymied .......................................................... 12 8. Professional Services Harder To Find ........................................................................ 13 9. Real Estate Challenges .............................................................................................. 13 B. The States -
Q1 2019 Your Cannabis Investment Resource
THE CANNIN REPORT | Q1/3 Q1 2019 Your Cannabis investment resource. THE CANNIN REPORT | Q1/3 table of contents 03 | welcome 04 | partner companies 05 | fundamental analysis 65 | cannin investing terms-to-know 67 | cannin cannabis terms-to-know 2 THE CANNIN REPORT | Q1/3 Cannin Report Q1 2019 – Cannabis Cultivators in the USA Welcome to Cannabis Investing in 2019! It’s crazy out there, we know. That’s why we put together our quarterly reports; to help you discern gold from fool’s gold. In the following pages you’ll find helpful terms-to-know for both cannabis and investing, deep analyses of 12 of the largest cannabis companies in the United States, and a piece on the important points on how to grow cannabis so you know what to look for when evaluating cannabis cultivators. Our team of industry experts has made this report easy to read, easy to understand, and easy to digest so that you’ll have the information you need to make the most profitable investments this calendar year. Thanks for purchasing, happy reading, and stay tuned to the next Cannin report (Q2) on the largest publicly traded hemp companies! Stephen Goldman & William Goodin Founders 3 THE CANNIN REPORT | Q1/3 4 THE CANNIN REPORT | Q1/3 55 THE CANNIN REPORT | Q1/3 A Short Explanation on How Cannin Evaluates Cannabis Companies Prior to investing in any stock, it’s important to do your homework. Fundamental analyses and technical analyses are essential to any stock evaluation and should be done with care. Cannin is here to help. -
Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C
NEW JERSEY CANNABIS REGULATORY COMMISSION Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C. 17:30 Adopted: August 19, 2021 by New Jersey Cannabis Regulatory Commission, Dianna Houenou, Chair. Filed: August 19, 2021 Authority: N.J.S.A. 24:6I-31 et seq. Effective Date: August 19, 2021 Expiration Date: August 19, 2022 This rule may be viewed or downloaded from the Commission’s website at nj.gov/cannabis. These rules are adopted pursuant to N.J.S.A. 24:6I-34(d)1a of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I- 31 et seq., and became effective upon acceptance for filing by the Office of Administrative Law. The specially adopted new rules shall be effective for a period not to exceed one year from the date of filing of the new rules, that is, until August 19, 2022. The Commission has provided this special adoption to the Attorney General, State Treasurer, Commissioner of Health, and Commissioner of Banking and Insurance for a consultation period, after which the Commission anticipates filing a proposal to readopt these rules with amendments reflecting the results of that consultation. In accordance with N.J.S.A. 24:6I-34(d)1b the rules, as readopted, will become effective upon acceptance for filing by the Office of Administrative Law if filed on or before the expiration date of the rules published herein. The adopted amendments will be effective upon publication in the New Jersey Register. Federal Standards Analysis The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act obliges the Cannabis Regulatory Commission to promulgate rules necessary or proper to enable it to carry out the Commission’s duties, functions, and powers with respect to overseeing the development, regulation, and enforcement of activities associated with the personal use of cannabis pursuant to P.L.2021, c.16. -
Bill Analysis and Fiscal Impact Statement
The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Committee on Agriculture BILL: SB 1766 INTRODUCER: Senator Powell SUBJECT: Sale of Hemp-derived Delta-8-tetrahydrocannabinol DATE: March 16, 2021 REVISED: ANALYST STAFF DIRECTOR REFERENCE ACTION 1. Becker Becker AG Pre-meeting 2. CJ 3. RC I. Summary: SB 1788 creates s. 581.218, F.S., to regulate the sale of hemp-derived delta-8- tetrahydrocannabinol (delta-8-THC) products. It provides definitions for certain terms relating to the sale of delta-8-THC products. The bill specifies that a sale of hemp-derived dela-8-THC products constitutes a delivery sale regardless of whether the person accepting the order for the delivery is located in Florida. A retailer who mails or ships any hemp-derived delta-8-THC products must: Obtain a certification from the consumer who is purchasing the product that he or she is 21 years of age or older; Include as part of the order’s shipping documents, in a clear and conspicuous manner, the following statement: “Hemp-derived Delta-8-Tetrahydrocannabinol Products: Florida law prohibits shipping to individuals under 21 years of age and requires the payment of all applicable taxes”; and Be in compliance with any labeling requirements, pursuant to Department of Agriculture and Consumer Services rule for the state hemp program. The bill outlines specific violations that are misdemeanors of the first degree. The bill is effective July 1, 2021 BILL: SB 1766 Page 2 II. -
A10 Anabolic Steroids Hardcore Info
CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone. -
(A-9-THC) Content in Herbal Cannabis Over Time
32 Current Drug Abuse Reviews, 2012, 5, 32-40 Increasing Delta-9-Tetrahydrocannabinol (-9-THC) Content in Herbal Cannabis Over Time: Systematic Review and Meta-Analysis Fidelia Cascini*,1, Carola Aiello2 and GianLuca Di Tanna3 1Istituto di Medicina Legale, Università Cattolica del S. Cuore, largo F. Vito, 1 00168 Roma, Italy 2Department of Informatics and Systemics, University ‘La Sapienza’, 00185 Rome, Italy 3Department of Public Health and Infectious Diseases, University "La Sapienza", 00185, Rome, Italy Abstract: Aim: The objective of this meta-analysis is to assess the data regarding changes in herbal cannabis potency over time (from 1970 to 2009). Methods: Systematic searches of 17 electronic scientific databases identified studies on this topic, within which 21 case series studies satisfied our inclusion criteria of reporting the mean tetrahydrocannabinol (THC) value per number of samples per year. No language, publication date, publication type or status restrictions were imposed. The study selection and data extraction processes were performed independently but uniformly by two authors, included screening, determination of eligibility and inclusion of the eligible studies in the systematic review, and a meta-analysis of the results on THC content in herbal cannabis samples. We considered papers and not monographic scientific publications, rejecting all studies that were not focused on the subject of this review. Results: Meta-analysis by year was performed on 21 studies containing 75 total mean THC observations from 1979 to 2009 using the random effects model. The results revealed much variability between studies. Further, there was a significant correlation between year and mean THC in herbal cannabis. The combined data indicated the correlation between year and mean THC in herbal cannabis, revealing a temporal trend of increasing potency (5% above the mean THC value in the Poisson regression analysis). -
As the Industry Develops, Cannabis and CBD Producers Sail Into the Dangerous Shoals of Product Recalls
As the Industry Develops, Cannabis And CBD Producers Sail Into the Dangerous Shoals of Product Recalls By: Richard M. Blau, Chairman Cannabis Law Group Now that the federal government has legalized hemp and defined lawful cannabidiol (CBD) produced from hemp, the market for CBD products has moved forward with exponential growth. In 2018, approximately $620 million worth of CBD products were sold in the United States. Popular economic advice platforms such as The Motley Fool report projections from economists and industry experts estimating future growth at approximately $24 billion by 2023. Growing CBD revenue from $620 million in 2018 to $23.7 billion by 2023 delivers a compound annual growth rate (CAGR) of 107%. While such statistics reflect a maturing market, so, too , do the arrival of product recalls. Recently, several CBD companies announced voluntary recalls of their products. Summit Labs’ Kore Organic Watermelon CBD Oil On May 12, 2020, Florida-based Summitt Labs, which produces a wide range of hemp-derived cannabidiol (CBD) products, announced a voluntary nationwide recall of its Kore Organic watermelon tincture after the Florida Department of Agriculture and Consumer Affairs conducted a test on a random sample and found high levels of lead. When ingested, lead can cause various symptoms such as pain, nausea and kidney damage; in prolonged exposure situations, lead poisoning has been shown to contribute to degraded brain functions. Summit Labs conducted its own test through an accredited, independent lab that found the lead levels in an acceptable range under state law. But, because the Florida officials found excess lead levels in the sample they tested, Summitt quickly moved to withdraw the product from retailers, who have been notified by phone and email. -
Know the Laws on Cannabis-Derived Products
Know the Laws on Cannabis-Derived Products Laws vary considerably around the country on the legality of marijuana (medical or recreational) and hemp- derived products containing cannabidiol (CBD). Before stocking any type of cannabis products in your store, it is essential that you understand both federal and state laws governing the sale and use of these products. Federal Law All strains of marijuana with a THC content exceeding .3 percent are illegal under federal law. The Drug Enforcement Administration classifies marijuana as a Schedule 1 drug and there are penalties under federal law for its sale or possession. Passage of the 2018 Farm Bill legalized the cultivation of low-THC hemp nationwide and the production, transport and sale of hemp-derived products with a THC level of less than .3 percent. This means the sale of CBD-based topical products and consumable CBD supplements is legal in all 50 states under federal law. However, many states that may allow some use of medical marijuana still classify other substances derived from cannabis — whether hemp or marijuana — as illegal. The FDA has approved four cannabis-related drugs — Epidiolex, Marinol, Syndros and Cesamet — and these are unquestionably legal to stock and dispense under federal law. It is important to understand that even if your state has legalized recreational or medical marijuana or products containing THC levels exceeding .3 percent, all those remain illegal under federal law. The U.S. Justice Dept., however, has for several years elected to not actively enforce federal law in states where marijuana laws contravene federal statutes. The FDA has concluded that THC and CBD products are excluded from the definition of a dietary supplement under section 201(ff)(3)(B) of the FD&C Act. -
The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I
STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I. Giancaspro, Nam-Cheol Kim, Jaap Venema, Susan de Mars, Jennifer Devine, Carlos Celestino, Christine E. Feaster, Ben A. Firschein, Mary S. Waddell, Stephen M. Gardner, and Earl Jones Jr.a ABSTRACT This Stimuli article analyzes the need for public quality standards for medical cannabis (defined herein as marijuana used for medical purposes under state laws) and the potential role of the U.S. Pharmacopeial Convention (USP) in addressing that need.1 Following legalization of the medical use of cannabis in several U.S. states and internationally, USP has received requests to investigate the advisability and feasibility of developing quality standards for medical cannabis. Development of quality standards for medical cannabis requires consideration of a wide range of scientific, legal, and policy issues that reach far beyond its classification as a botanical drug or herbal medicine. This article discusses the current regulatory and scientific landscape regarding medical cannabis, identifies issues related to the lack of quality standards for medical cannabis, and explores potential options for developing quality standards. USP seeks input from stakeholders on whether USP should proceed with development of quality standards for medical cannabis and if so, what approaches should be utilized to establish such standards. LEGAL AND REGULATORY LANDSCAPE The federal and state regulatory environment surrounding the medical use of cannabis involves many federal agencies and various different state laws. The evolving legal environment is an important consideration when evaluating the advisability and feasibility of USP developing a public standard for cannabis. -
Liberty Health Sciences Inc. Management's Discussion
LIBERTY HEALTH SCIENCES INC. MANAGEMENT’S DISCUSSION & ANALYSIS This management discussion and analysis (“MD&A”) of the financial condition and results of operations of Liberty Health Sciences Inc., (the “Company” or “Liberty”), is for the three and six month period ended August 31, 2019, and 2018. It is supplemental to, and should be read in conjunction with the Company’s unaudited interim condensed consolidated financial statements and the accompanying notes for the three and six month period ended August 31, 2019, and 2018 (the “Q2 2020, and Q2 2019 Financials”) as well as the audited consolidated financial statements for the year ended February 28, 2019. The Company’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). This MD&A has been prepared by reference to the MD&A disclosure requirements established under National Instrument 51-102 “Continuous Disclosure Obligations” (“NI 51-102”) of the Canadian Securities Administrators. Additional information regarding Liberty Health Sciences Inc. is available on our website at www.libertyhealthsciences.com or through the SEDAR website at www.sedar.com. In this MD&A, reference is made to gross profit before biological asset adjustments, gross margin before biological asset adjustments and adjusted earnings before interest, tax, depreciation and amortization (“EBITDA”), which are not measures of financial performance under IFRS and may not be comparable to similarly titled measures used by other companies. The Company calculates each as follows: • Gross profit before biological asset adjustments is equal to gross profit less the non-cash change in the fair value on harvest and less the non-cash change in the fair value on cost of goods sold, if any. -
CBD) Information About CBD in Cannabis and Hemp Products Under the New Cannabis Act
ALL ABOUT CANNABIDIOL (CBD) Information about CBD in cannabis and hemp products under the new Cannabis Act WHAT IS CBD? The cannabis plant contains hundreds of different chemical constituents, such as cannabinoids, terpenes and flavonoids. Currently, over 100 chemical substances collectively known as cannabinoids have been identified. Cannabinoids that are derived from cannabis plants are sometimes referred to as phytocannabinoids. Cannabidiol (CBD) is one of these cannabinoids. Unlike tetrahydrocannabinol (THC) - the most well-known cannabinoid in cannabis, responsible for the high or intoxication of consuming cannabis - CBD does not produce a high or intoxicating effect. However, there is some evidence that CBD may influence some of the effects that THC has on the brain. CBD is also being studied for its possible therapeutic uses; it has received market approval in the United States for two severe forms of epilepsy. CBD can be found in varieties of the cannabis plant, including hemp plants. All phytocannabinoids, whether derived from a cannabis plant or produced by synthesis, including both THC and CBD, are regulated under the new Cannabis Act and its regulations, which came into force on October 17, 2018. HOW IS CBD REGULATED IN CANADA? Under the Cannabis Act, many activities with phytocannabinoids, CBD included, remain prohibited, except for the specific cases authorized by the Act and its regulations, which include strict controls on possession, production, sale, and distribution. While Health Canada oversees the production of cannabis products, the provinces and territories oversee the distribution and retail aspects of the cannabis supply chain. Health Canada remains responsible for overseeing the distribution and sale of cannabis and any CBD-containing cannabis products for medical purposes.